

Summary Public Assessment Report

Methenamine hippurate Zentiva (methenamine hippurate)

SE/H/2516/01/DC

Summary Public Assessment Report

Methenamine hippurate Zentiva
methenamine hippurate

Tablet, 1 g

This is a summary of the public assessment report (PAR) for Methenamine hippurate Zentiva. It explains how the assessment was made and why the authorisation was recommended as well as the conditions of use. It is not intended to provide practical advice on how to use the product.

For practical information about the use of the product, patients should read the package leaflet or contact their doctor or pharmacist.

What is Methenamine hippurate Zentiva and what is it used for?

The product is a 'generic medicine'. This means that it is similar to a 'reference medicine' already authorised in the European Union (EU) called Hiprex.

Methenamine hippurate Zentiva is used:

- as a urinary tract anti-bacterial agent (bactericidal) that is used to prevent relapsing urinary tract infections.
- during urinary examinations and urinary treatments to reduce the risk of infections.
- in people who carry urinary tract catheter for a long time.

How does Methenamine hippurate Zentiva work?

Methenamine hippurate Zentiva contains the active substance methenamine hippurate.

The preventive treatment with this medicine reduces the risks for new urinary tract infections with repeated painful mictions (peeing) and bad smelling urine.

How is Methenamine hippurate Zentiva used?

The pharmaceutical form is tablet for oral use.

Please read section 3 of the package leaflet for detailed information on dosing recommendations, the route of administration, and the duration of treatment.

The medicine can only be obtained with a prescription in Sweden.

What benefits of Methenamine hippurate Zentiva have been shown in studies?

Because the product is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine, Hiprex. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

What are the possible side effects from Methenamine hippurate Zentiva?

Because the product is a generic medicine, its benefits and possible side effects are taken as being the same as the reference medicine.

For the full list of side effects, see section 4 of the package leaflet.

For the full list of restrictions, see the package leaflet.

Why is Methenamine hippurate Zentiva approved?

It was concluded that, in accordance with EU requirements, the product has been shown to have comparable quality and is considered to be bioequivalent to the reference medicine. Therefore, the Swedish Medical Products Agency decided that, as for Hiprex, the benefits are greater than its risks and recommended that it can be approved for use.

What measures are being taken to ensure the safe and effective use of Methenamine hippurate Zentiva?

A risk management plan has been developed to ensure that the product is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet, including the appropriate precautions to be followed by healthcare professionals and patients.

Known side effects are continuously monitored. Furthermore, new safety signals reported by patients/healthcare professionals will be monitored/reviewed continuously as well.

Other information about Methenamine hippurate Zentiva

The full PAR for Methenamine hippurate Zentiva can be found on the following website: [MRI - Home](#). For more information about treatment with Methenamine hippurate Zentiva, please read the package leaflet or contact your doctor or pharmacist.

This summary was last updated in 2025-10.